Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients

European Neurology

Volumn 64, Issue 3, 2010, Pages 186-190

  Nagane, Yuriko ^a   Suzuki, Shigeaki ^b   Suzuki, Norihiro ^b   Utsugisawa, Kimiaki ^a  

^a Hanamaki General Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERTENSION; INFORMED CONSENT; MALE; MICROEMULSION; MYASTHENIA GRAVIS; OPEN STUDY; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 77955602978     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319172     Document Type: Article

References (17)

1. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
2. Fujii Y, Lindstrom J: Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. J Immunol 1988;141:3361-3369.
3. Mokhtarian F, Pino M, Ofosu-Appiah W, Grob D: Phenotypic and functional characterization of T cells from patients with myasthenia gravis. J Clin Invest 1990;86:2099-2108.
4. ®) in organ transplantation. Drugs 2001;61:1957-2016.
5. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142.
6. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myast henia g ravis. N Engl J Med 1987;316:719-724.
7. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
8. Bonifati DM, Angelini C: Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997;244:542-547.
9. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55:448-450.
10. 2 monitoring: a European consensus. Transplant Int 2005;18:768-778.
11. Utsugisawa K, Nagane Y, Suzuki S, Suzuki N: Monitoring treatment with cyclosporine microemulsion in myasthenia gravis. Eur J Neurol 2008;15:598-604.
12. Pascuzzi RM, Coslett HB, Johns TR: Longterm corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
13. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
14. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K: Factors a ssociated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 2010;41:212-218.
15. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America: Jaretzki III A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al: Myasthenia gravis: recommendation for clinical research standards. Neurology 2000;55:16-23.
16. Truhan AP, Ahmed AR: Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375-391.
17. Brown ES, Suppes T: Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psychiatry 1998;5:239-246.